Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

PYK2 promotes HER2-positive breast cancer invasion.

Al-Juboori SI, Vadakekolathu J, Idri S, Wagner S, Zafeiris D, Pearson JR, Almshayakhchi R, Caraglia M, Desiderio V, Miles AK, Boocock DJ, Ball GR, Regad T.

J Exp Clin Cancer Res. 2019 May 22;38(1):210. doi: 10.1186/s13046-019-1221-0.

2.

A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study.

Wagner S, Vadakekolathu J, Tasian SK, Altmann H, Bornhäuser M, Pockley AG, Ball GR, Rutella S.

Blood Adv. 2019 Apr 23;3(8):1330-1346. doi: 10.1182/bloodadvances.2018030726.

3.

Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.

Thompson AM, Clements K, Cheung S, Pinder SE, Lawrence G, Sawyer E, Kearins O, Ball GR, Tomlinson I, Hanby A, Thomas JSJ, Maxwell AJ, Wallis MG, Dodwell DJ; Sloane Project Steering Group (NHS Prospective Study of Screen-Detected Non-invasive Neoplasias).

Eur J Cancer. 2018 Sep;101:210-219. doi: 10.1016/j.ejca.2018.06.027. Epub 2018 Aug 6.

PMID:
30092498
4.

An Artificial Neural Network Integrated Pipeline for Biomarker Discovery Using Alzheimer's Disease as a Case Study.

Zafeiris D, Rutella S, Ball GR.

Comput Struct Biotechnol J. 2018 Feb 21;16:77-87. doi: 10.1016/j.csbj.2018.02.001. eCollection 2018. Review.

5.

MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer.

Vadakekolathu J, Al-Juboori SIK, Johnson C, Schneider A, Buczek ME, Di Biase A, Pockley AG, Ball GR, Powe DG, Regad T.

Cell Death Dis. 2018 Mar 1;9(3):344. doi: 10.1038/s41419-018-0364-9.

6.

The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.

Abdel-Fatah TMA, Rees RC, Pockley AG, Moseley P, Ball GR, Chan SYT, Ellis IO, Miles AK.

Oncotarget. 2017 Nov 18;8(68):112245-112257. doi: 10.18632/oncotarget.22496. eCollection 2017 Dec 22.

7.

Multicentre study of patient-reported and clinical outcomes following immediate and delayed Autologous Breast Reconstruction And Radiotherapy (ABRAR study).

Steele KH, Macmillan RD, Ball GR, Akerlund M, McCulley SJ.

J Plast Reconstr Aesthet Surg. 2018 Feb;71(2):185-193. doi: 10.1016/j.bjps.2017.10.030. Epub 2017 Nov 10.

PMID:
29203259
8.

Discovery and application of immune biomarkers for hematological malignancies.

Zafeiris D, Vadakekolathu J, Wagner S, Pockley AG, Ball GR, Rutella S.

Expert Rev Mol Diagn. 2017 Nov;17(11):983-1000. doi: 10.1080/14737159.2017.1381560. Epub 2017 Sep 25. Review.

PMID:
28927305
9.

Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.

Arora A, Parvathaneni S, Aleskandarany MA, Agarwal D, Ali R, Abdel-Fatah T, Green AR, Ball GR, Rakha EA, Ellis IO, Sharma S, Madhusudan S.

Mol Cancer Ther. 2017 Jan;16(1):239-250. doi: 10.1158/1535-7163.MCT-16-0290. Epub 2016 Nov 11.

10.

Glucolipotoxicity initiates pancreatic β-cell death through TNFR5/CD40-mediated STAT1 and NF-κB activation.

Bagnati M, Ogunkolade BW, Marshall C, Tucci C, Hanna K, Jones TA, Bugliani M, Nedjai B, Caton PW, Kieswich J, Yaqoob MM, Ball GR, Marchetti P, Hitman GA, Turner MD.

Cell Death Dis. 2016 Aug 11;7(8):e2329. doi: 10.1038/cddis.2016.203.

11.

Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series.

Green AR, Soria D, Stephen J, Powe DG, Nolan CC, Kunkler I, Thomas J, Kerr GR, Jack W, Cameron D, Piper T, Ball GR, Garibaldi JM, Rakha EA, Bartlett JM, Ellis IO.

J Pathol Clin Res. 2016 Jan 15;2(1):32-40. doi: 10.1002/cjp2.32. eCollection 2016 Jan.

12.

Erratum to: Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.

Green AR, Soria D, Powe DG, Nolan CC, Aleskandarany M, Szász MA, Tőkés AM, Ball GR, Garibaldi JM, Rakha EA, Kulka J, Ellis IO.

Breast Cancer Res Treat. 2016 Aug;159(1):199. No abstract available.

PMID:
27447877
13.

SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.

Abdel-Fatah TMA, Agarwal D, Liu DX, Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG, Rees RC, Caldas C, Ellis IO, Ball GR, Chan SYT.

Lancet Oncol. 2016 Jul;17(7):1004-1018. doi: 10.1016/S1470-2045(16)00174-1. Epub 2016 Jun 14.

PMID:
27312051
14.

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.

Green AR, Soria D, Powe DG, Nolan CC, Aleskandarany M, Szász MA, Tőkés AM, Ball GR, Garibaldi JM, Rakha EA, Kulka J, Ellis IO.

Breast Cancer Res Treat. 2016 May;157(1):65-75. doi: 10.1007/s10549-016-3804-1. Epub 2016 Apr 26. Erratum in: Breast Cancer Res Treat. 2016 Aug;159(1):199.

15.

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.

Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-Rodriguez M, Macmillan RD, Ball GR, Caldas C, Madhusudan S, Ellis IO, Rakha EA.

Br J Cancer. 2016 Apr 12;114(8):917-28. doi: 10.1038/bjc.2016.46. Epub 2016 Mar 8.

16.

Accuracy of GE digital breast tomosynthesis vs supplementary mammographic views for diagnosis of screen-detected soft-tissue breast lesions.

Cornford EJ, Turnbull AE, James JJ, Tsang R, Akram T, Burrell HC, Hamilton LJ, Tennant SL, Bagnall MJ, Puri S, Ball GR, Chen Y, Jones V.

Br J Radiol. 2016;89(1058):20150735. doi: 10.1259/bjr.20150735. Epub 2015 Nov 11.

17.

HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.

Abdel-Fatah TM, McArdle SE, Agarwal D, Moseley PM, Green AR, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY.

Clin Cancer Res. 2016 Feb 15;22(4):905-14. doi: 10.1158/1078-0432.CCR-15-0610. Epub 2015 Aug 3.

19.

Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer.

Coveney C, Boocock DJ, Rees RC, Deen S, Ball GR.

Microarrays (Basel). 2015 Jul 17;4(3):324-38. doi: 10.3390/microarrays4030324.

20.

Artificial neural network inference (ANNI): a study on gene-gene interaction for biomarkers in childhood sarcomas.

Tong DL, Boocock DJ, Dhondalay GK, Lemetre C, Ball GR.

PLoS One. 2014 Jul 15;9(7):e102483. doi: 10.1371/journal.pone.0102483. eCollection 2014.

21.

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.

Abdel-Fatah TM, McArdle SE, Johnson C, Moseley PM, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY.

Br J Cancer. 2014 May 13;110(10):2450-61. doi: 10.1038/bjc.2014.168. Epub 2014 Apr 22.

22.

DACH1: its role as a classifier of long term good prognosis in luminal breast cancer.

Powe DG, Dhondalay GK, Lemetre C, Allen T, Habashy HO, Ellis IO, Rees R, Ball GR.

PLoS One. 2014 Jan 2;9(1):e84428. doi: 10.1371/journal.pone.0084428. eCollection 2014.

23.

Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers.

Green AR, Powe DG, Rakha EA, Soria D, Lemetre C, Nolan CC, Barros FF, Macmillan RD, Garibaldi JM, Ball GR, Ellis IO.

Br J Cancer. 2013 Oct 1;109(7):1886-94. doi: 10.1038/bjc.2013.528. Epub 2013 Sep 5.

24.

A quantifier-based fuzzy classification system for breast cancer patients.

Soria D, Garibaldi JM, Green AR, Powe DG, Nolan CC, Lemetre C, Ball GR, Ellis IO.

Artif Intell Med. 2013 Jul;58(3):175-84. doi: 10.1016/j.artmed.2013.04.006. Epub 2013 Jun 18.

PMID:
23791088
25.

Biomarker identification in breast cancer: Beta-adrenergic receptor signaling and pathways to therapeutic response.

Kafetzopoulou LE, Boocock DJ, Dhondalay GK, Powe DG, Ball GR.

Comput Struct Biotechnol J. 2013 May 21;6:e201303003. doi: 10.5936/csbj.201303003. eCollection 2013.

26.

Identification of novel breast cancer-associated transcripts by UniGene database mining and gene expression analysis in normal and malignant cells.

Laversin SA, Phatak VM, Powe DG, Li G, Miles AK, Hughes DC, Ball GR, Ellis IO, Gritzapis AD, Missitzis I, McArdle SE, Rees RC.

Genes Chromosomes Cancer. 2013 Mar;52(3):316-29. doi: 10.1002/gcc.22031. Epub 2012 Dec 8.

PMID:
23225347
27.

Lack of expression of the proteins GMPR2 and PPARα are associated with the basal phenotype and patient outcome in breast cancer.

Baker BG, Ball GR, Rakha EA, Nolan CC, Caldas C, Ellis IO, Green AR.

Breast Cancer Res Treat. 2013 Jan;137(1):127-37. doi: 10.1007/s10549-012-2302-3. Epub 2012 Dec 4.

PMID:
23208589
28.

TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome.

Aleskandarany MA, Negm OH, Rakha EA, Ahmed MA, Nolan CC, Ball GR, Caldas C, Green AR, Tighe PJ, Ellis IO.

Breast Cancer Res Treat. 2012 Nov;136(2):419-27. doi: 10.1007/s10549-012-2249-4. Epub 2012 Oct 4.

PMID:
23053644
29.

A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences.

Shaaban AM, Ball GR, Brannan RA, Cserni G, Di Benedetto A, Dent J, Fulford L, Honarpisheh H, Jordan L, Jones JL, Kanthan R, Maraqa L, Litwiniuk M, Mottolese M, Pollock S, Provenzano E, Quinlan PR, Reall G, Shousha S, Stephens M, Verghese ET, Walker RA, Hanby AM, Speirs V.

Breast Cancer Res Treat. 2012 Jun;133(3):949-58. doi: 10.1007/s10549-011-1856-9. Epub 2011 Nov 18.

PMID:
22094935
30.

A simpler method of preprocessing MALDI-TOF MS data for differential biomarker analysis: stem cell and melanoma cancer studies.

Tong DL, Boocock DJ, Coveney C, Saif J, Gomez SG, Querol S, Rees R, Ball GR.

Clin Proteomics. 2011 Sep 19;8:14. doi: 10.1186/1559-0275-8-14.

31.

MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease.

Chang KH, Miller N, Kheirelseid EA, Lemetre C, Ball GR, Smith MJ, Regan M, McAnena OJ, Kerin MJ.

Int J Colorectal Dis. 2011 Nov;26(11):1415-22. doi: 10.1007/s00384-011-1279-4. Epub 2011 Jul 8.

PMID:
21739196
32.

Calpastatin is associated with lymphovascular invasion in breast cancer.

Storr SJ, Mohammed RA, Woolston CM, Green AR, Parr T, Spiteri I, Caldas C, Ball GR, Ellis IO, Martin SG.

Breast. 2011 Oct;20(5):413-8. doi: 10.1016/j.breast.2011.04.002. Epub 2011 May 4.

33.

The vibrant soundbridge: design and development.

Ball GR.

Adv Otorhinolaryngol. 2010;69:1-13. doi: 10.1159/000318516. Epub 2010 Jul 5.

PMID:
20610908
34.

High-throughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich alpha-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration.

Kay RG, Barton C, Velloso CP, Brown PR, Bartlett C, Blazevich AJ, Godfrey RJ, Goldspink G, Rees R, Ball GR, Cowan DA, Harridge SD, Roberts J, Teale P, Creaser CS.

Rapid Commun Mass Spectrom. 2009 Oct;23(19):3173-82. doi: 10.1002/rcm.4237.

PMID:
19718777
35.

The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer.

Zhang H, Rakha EA, Ball GR, Spiteri I, Aleskandarany M, Paish EC, Powe DG, Macmillan RD, Caldas C, Ellis IO, Green AR.

Breast Cancer Res Treat. 2010 May;121(1):41-51. doi: 10.1007/s10549-009-0450-x. Epub 2009 Jul 10.

PMID:
19590950
36.

Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome.

Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA, Grainge MJ, Ball GR, Abdelghany MK, Martinez-Pomares L, Heery DM, Ellis IO.

Cancer Res. 2009 May 1;69(9):3802-9. doi: 10.1158/0008-5472.CAN-08-3907. Epub 2009 Apr 14.

37.

A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks.

Lancashire LJ, Powe DG, Reis-Filho JS, Rakha E, Lemetre C, Weigelt B, Abdel-Fatah TM, Green AR, Mukta R, Blamey R, Paish EC, Rees RC, Ellis IO, Ball GR.

Breast Cancer Res Treat. 2010 Feb;120(1):83-93. doi: 10.1007/s10549-009-0378-1. Epub 2009 Apr 4.

PMID:
19347577
38.

An introduction to artificial neural networks in bioinformatics--application to complex microarray and mass spectrometry datasets in cancer studies.

Lancashire LJ, Lemetre C, Ball GR.

Brief Bioinform. 2009 May;10(3):315-29. doi: 10.1093/bib/bbp012. Epub 2009 Mar 23.

PMID:
19307287
39.

Identification of gene transcript signatures predictive for estrogen receptor and lymph node status using a stepwise forward selection artificial neural network modelling approach.

Lancashire LJ, Rees RC, Ball GR.

Artif Intell Med. 2008 Jun;43(2):99-111. doi: 10.1016/j.artmed.2008.03.001. Epub 2008 Apr 16.

PMID:
18420392
40.

Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999.

Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA, Robertson JF, Mitchell MJ, Ball GR, Haybittle JL, Elston CW.

Eur J Cancer. 2007 Jul;43(10):1548-55. Epub 2007 Feb 26.

PMID:
17321736
41.

Reading the prognosis of the individual with breast cancer.

Blamey RW, Pinder SE, Ball GR, Ellis IO, Elston CW, Mitchell MJ, Haybittle JL.

Eur J Cancer. 2007 Jul;43(10):1545-7. Epub 2007 Feb 22.

PMID:
17320376
42.

A new implantable middle ear hearing device for mixed hearing loss: A feasibility study in human temporal bones.

Huber AM, Ball GR, Veraguth D, Dillier N, Bodmer D, Sequeira D.

Otol Neurotol. 2006 Dec;27(8):1104-9.

PMID:
17031322
43.

Implantable hearing device performance measured by laser Doppler interferometry.

Gan RZ, Wood MW, Ball GR, Dietz TG, Dormer KJ.

Ear Nose Throat J. 1997 May;76(5):297-9, 302, 305-9. Review.

PMID:
9170711
44.

Scanning laser Doppler vibrometry of the middle ear ossicles.

Ball GR, Huber A, Goode RL.

Ear Nose Throat J. 1997 Apr;76(4):213-8, 220, 222.

PMID:
9127520
45.

A high velocity impact device for obtaining multiple, contiguous, myocardial biopsies.

Hearse DJ, Yellon DM, Chappell DA, Wyse RK, Ball GR.

J Mol Cell Cardiol. 1981 Feb;13(2):197-206. No abstract available.

PMID:
7265243

Supplemental Content

Support Center